Search results :

Topotecan

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: L01XX17

Side effects

Options: Show MedDRA Preferred Terms,   display all 27 labels

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Leukopenia very common, 91% - 97% x x x x x x x x x x x x x x x x x x
Alopecia very common, 0% - 54% x x x x x x x x x x x x x x x x x x x
Anaemia very common, 1.9% - 98% x x x x x x x x x x x x x x x x x x x x
Neutropenia very common, 1% - 97% x x x x x x x x x x x x x x x x x x x x
Body temperature increased very common, 0% - 43% x x x x x x x x x x x x x x x x x x x x
Colitis very common x x x x
Infection very common, 0% - 43% x x x x x x x x x x x x x x x x x x x
Thrombocytopenia postmarketing — 0.5% - 81% x x x x x x x x x x x x x x x x x x x x
Mucosal inflammation very common, 14% x x x x x
Febrile neutropenia very common, 0% - 28% x x x x x x x x x x x x x x x
Mediastinal disorder 5% - 14% x x x x x x x x x x x x x x x
Nausea very common, 0% - 64% x x x x x x x x x x x x x x x x x x x
Fatigue very common, 0% - 29% x x x x x x x x x x x x x x x x x x x
Pneumonia 2% - 8% x x x x x x x x x x
Asthenia very common, 0% - 25% x x x x x x x x x x x x x x x x x x
Dizziness common x x
Dyspnoea common, 1% - 22% x x x x x x x x x x x x x
Pain 1% - 50% x x x x x x x x x x x
Pancytopenia common x x x x x x x x
Paraesthesia common x x x x x x x x x x x x
Alanine aminotransferase increased common x x x x
Sepsis common, 0% - 43% x x x x x x x x x x x x x x x x x x
Infestation NOS 2% - 43% x x x x x x x x x x x x x x x
Intestinal obstruction 0.8% - 5% x x x x x
Vomiting very common, 0% - 45% x x x x x x x x x x x x x x x x x x x
Diarrhoea very common, 0% - 32% x x x x x x x x x x x x x x x x x x x
Malaise common, 0.3% - 5% x x x x x x x x x x x
Abdominal pain postmarketing — 1% - 22% x x x x x x x x x x x x x x x x x x
Anorexia very common, 0% - 19% x x x x x x x x x x x x x x x x x x x
Constipation very common, 0% - 29% x x x x x x x x x x x x x x x x x x
Malnutrition 1% - 19% x x x x x x x x x x x x x x x
Myalgia 0% - 4% x x x x x
Cough 0% - 15% x x x x x x x x x x x x x
Rash common, 0% - 16% x x x x x x x x x x x x x x x x x x
Headache common, 0% - 18% x x x x x x x x x x x x x
Hyperbilirubinaemia common, 0.8% - 1% x x x x x x x x
Nervous system disorder 1% - 18% x x x x x x x x
Arthralgia 0.2% - 3% x x x x x
Chest pain 0.3% - 2% x x x x
Hypersensitivity common, 0% - 6% x x x x x x x x x x x x x x
Neuropathy uncommon, 0% - 30% x x x x x x x x x x
Hypoaesthesia uncommon x x
Paresis uncommon x x
Neuropathy peripheral uncommon x x
Haemorrhage postmarketing — 1% - 14% x x x x x x x x x x x x x x x x x
Stomatitis very common, 0% - 18% x x x x x x x x x x x x x
Anaphylactic shock rare x x x x x
Angioedema postmarketing, rare x x x x x x x x x x x x x x x
Dermatitis postmarketing x x x x x x x x x x
Extravasation very rare, postmarketing x x x x x x x x x x x x x x
Gastrointestinal disorder postmarketing — 4% - 6% x x x x x x x x x x x x x x x
Immune system disorder postmarketing x x x x x x x x x x x x x x x
Lung disorder postmarketing x x x x x x x
Pruritus postmarketing, common x x x x x x x x x x x x x x x
Urticaria rare x x x x x x x x x
Unspecified disorder of skin and subcutaneous tissue postmarketing x x x x x x x x x x x x x
Interstitial lung disease postmarketing, rare x x x x x x x x x x x x x x x x
Anaphylactoid reaction postmarketing x x x x x x x x x x
Neutropenic colitis postmarketing, very common x x x x x x x x x x x x x x x x
Blood and lymphatic system disorders postmarketing x x x x x x x x x x x x x x x
Back pain x x x x x
Pleuritic pain x x
Dysmenorrhoea x x
Ear pain x x
Epistaxis x x
Cardiac arrest x x
Heartburn x x
Lethargy x x
Cramp muscle x x
Neoplasm x x x x x
Neuralgia x x
Pelvic pain x x
Pharyngitis 0% - 1% x x x x x x x x x
Pleural effusion x x
Pulmonary embolism x x
Acute respiratory distress syndrome x x
Rhinitis x x
Sweating x x
Angiopathy x x x x x x x
Weight increased x x
Chills x x
Acute leukaemia x
Bone pain x x x x x x
Aspartate aminotransferase increased x x
Rash erythematous x x x x
Bullous eruption x x x x
Lung neoplasm malignant x
Hepatobiliary disease x x x x x x x x x x x x x x x
Blood bilirubin increased x x x x x x x x x x
Rash maculo-papular x x x x
Rigors x x
Hepatic pain x x
Thrombocytopenia aggravated x x
Tumour pain x x
Myelosuppression x x x x x x x
Respiratory failure x x
Metastatic carcinoma x
Dyspareunia x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

topotecan hydrochloride / Hycamtin

Side effects:8
Source:FDA

TOPOTECAN

Side effects:13
Source:FDA Structured Product Label

Topotecan

Side effects:29
Source:BC Cancer

topotecan / topotecan

Side effects:40
Source:EMA

topotecan / topotecan

Side effects:40
Source:EMA

topotecan / topotecan

Side effects:40
Source:EMA

topotecan / topotecan hydrochloride

Side effects:40
Source:EMA

topotecan / topotecan

Side effects:41
Source:EMA

TOPOTECAN HYDROCHLORIDE / HYCAMTIN

Side effects:43
Source:FDA

TOPOTECAN

Side effects:47
Source:FDA Structured Product Label

Topotecan hydrochloride / HYCAMTIN POWDER FOR INJECTION

Side effects:47
Source:medicines.org.au

TOPOTECAN (TOPOTECAN HYDROCHLORIDE) / HYCAMTIN

Side effects:49
Source:Health Canada

TOPOTECAN

Side effects:49
Source:FDA Structured Product Label

TOPOTECAN

Side effects:49
Source:FDA Structured Product Label

topotecan

Side effects:49
Source:FDA Structured Product Label

TOPOTECAN

Side effects:50
Source:FDA Structured Product Label

TOPOTECAN

Side effects:50
Source:FDA Structured Product Label

Topotecan

Side effects:75
Source:FDA Structured Product Label

TOPOTECAN

Side effects:80
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label